What are current studies doing when high levels of blood biomarkers for Alzheimer’s are found? Elizabeth Tracey reports

Podcast: Download (Duration: 1:05 — 1.5MB)

Subscribe: RSS

High blood biomarkers for Alzheimer’s disease found by the newly FDA approved blood test indicate the presence of two proteins in the brain called amyloid and tau. Abhay Moghakar, a neurologist and blood biomarkers expert at Johns Hopkins, says some people who’ve gotten these kinds of results are enrolling in clinical trials.

Moghakar: People with high biomarkers, essentially abnormal levels of amyloid and tau but with no cognitive symptoms are getting targeted therapies to either amyloid or tau to see if that would prevent the progression to Alzheimer's disease.  Or participate in a lifestyle intervention study if you have these abnormal biomarkers to see if that would reduce your progression to develop cognitive symptoms. What these biomarkers are telling us is that pathology starts decades earlier so you actually have a window of time to do these interventions.        :31

Moghakar predicts both lifestyle interventions and medications are likely to be important in interrupting progression. At Johns Hopkins, I’m Elizabeth Tracey.